Jul 16th 2012 - Edison Investment Research today published a report on TiGenix entitled "Fistula Relief On Track". In summary, the report says:
TiGenix has made good progress in developing its EU stem cell business. The Dutch healthcare system now fully reimburses ChondroCelect enabling TiGenix to invest in marketing and product support into Holland. The crucial Cx601 study in perianal fistulas started on 10 July as expected. The Cx621 safety study showed that intralymphatic groin injection of adipose stem cells was safe and well tolerated. A US partner on Cx601 may be agreed in H212-H113.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
